Q-omics provides the consensus-scored MIR6503 profile across patient tissues and cancer cell-line models. MIR6503 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MIR6503 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, MIR6503 RNA expression shows 15,568 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where MIR6503 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6503 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6503 survival associations across molecular data types. MIR6503 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6503 RNA expression–survival associations across cancer types. High MIR6503 expression shows unfavorable associations in READ, LGG and TGCT, but favorable associations in HNSC, ACC and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .008). Together, the overview and detailed table identify HNSC as the clearest survival context for MIR6503 RNA expression.
This table summarizes MIR6503 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6503. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6503 shows lower tumor expression in BRCA, COAD, LUSC and UCEC and higher tumor expression in KIRC and STAD. The KIRC box plot shows higher MIR6503 RNA expression in tumor versus normal tissue (log2 FC = +1.085, t-test p < 0.001).
This table shows molecular features associated with MIR6503 in patient tissues and cancer cell lines. In patient samples, MIR6503 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
